On behalf of the head of the FMBA Veronika Skvortsova was initiated comparative clinical studies of drugs hydroxychloroquine, mefloquine and Russian drug kalidevi that will be used for the treatment of patients with coronavirus infection. This was reported by the press service of the FMBA.
“6 April 2020 on the basis of SSC center named after them. A. I. Burnazyan of FMBA of Russia has begun clinical studies of drugs and mefloquine hydroxychloroquine in comparison with the drug kalidevi in three groups of patients with different severity”, – said the head of the FMBA of Russia Veronika Skvortsova.
Clinical studies will be conducted involving patients with the new coronavirus infection of SARS-CoV-2, which will arrive in SSC center named after them. A. I. Burnazyan of FMBA of Russia. In KEY patients will be included after signing the informed consent.